NYSE: EVHEvolent Health Inc Stock
$9.27-0.04 (-0.43%)
Updated May 13, 2025
EVH Price
$9.27
Fair Value Price
N/A
Market Cap
$1.09B
52 Week Low
$8.35
52 Week High
$33.63
P/E
-7.6x
P/B
1.16x
P/S
0.46x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.40B
Earnings
-$116.94M
Gross Margin
15.2%
Operating Margin
-3.68%
Profit Margin
-5.9%
Debt to Equity
1.63
Operating Cash Flow
$18M
Beta
1.02
Next Earnings
Jun 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
EVH Overview
Evolent Health, Inc. offers administrative solutions to healthcare providers in the U.S. Offerings include financial and administrative management services, risk management, and analytics and reporting. The company's proprietary technology aggregates and analyzes data and manages care workflows to deliver cost-effective care. The company was founded in 2011 and is headquartered in Arlington, VA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EVH's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
A
EVH
Ranked#44 of 44
Ranked#44 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $24.95 | A | |
| $16.41 | A | |
| $125.93 | A |
Be the first to know about important EVH news, forecast changes, insider trades & much more!
EVH News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EVH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EVH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EVH is good value based on its book value relative to its share price (1.16x), compared to the US Health Information Services industry average (3.71x)
P/B vs Industry Valuation
EVH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EVH due diligence checks available for Premium users.
Valuation
EVH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.6x
Industry
45.06x
Market
25.53x
EVH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.16x
Industry
3.71x
EVH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EVH's financial health
Profit margin
Revenue
$483.6M
Net Income
-$64.6M
Profit Margin
-14.9%
EVH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EVH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.7B
Liabilities
$1.5B
Debt to equity
1.63
EVH's short-term liabilities ($739.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EVH's long-term liabilities ($785.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EVH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EVH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$4.6M
Investing
-$13.1M
Financing
$107.9M
EVH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EVH vs Health Information Service Stocks
Evolent Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.